Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)

Learn more about:
Related Clinical Trial
The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis Long-term Use of Mifepristone in the Treatment of Adenomyosis Radiofrequency Ablation of Adenomyosis Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)

Official Title

Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)

Brief Summary

      MRI-guided high intensity focused ultrasound (MRI-HIFU) has been proven to be a safe and
      effective method in treating uterine fibroids and also adenomyosis. However, systematic
      studies on the effect of this treatment on factors affecting fertility are still lacking.
      Also quite little is known about body's systemic response to MRI-HIFU. Thus the aim of this
      study is to obtain more information on the systemic response of the body to the
      HIFU-treatment when treating non-malignant disease as well as to study the effect of MRI-HIFU
      on factors affecting fertility. Women with symptomatic uterine fibroids or adenomyosis
      suitable for MRI-HIFU treatment are recruited to this study. The severity of symptoms will be
      assessed with UFS-QoL and the same questionnaire will also be used in follow-up 3, 6 and 12
      months after treatment. Blood, urine and endometrium samples will be collected pre- and
      postoperatively and during follow-up 3, 6 and 12 months after the treatment. From these
      samples detailed analysis of the immunological, inflammatory and hormonal response will be
      performed. As this is the first study in Finland of treating uterine fibroids and adenomyosis
      using MRI-HIFU, also a report about the efficacy of the MRI-HIFU in treating the uterine
      disorders will be published, and a key tool in assessing the treatment outcome would be the
      UFS-QoL questionnaire.

      Also new methods for improving patient selection as well as treatment efficacy will be
      evaluated in this study.

Study Type


Primary Outcome

Technical efficacy of HIFU for treatment of uterine fibroids as assessed by a change in the Symptom Severity Score


Uterine Fibroids



Study Arms / Comparison Groups

 Patients treated with MRI-HIFU


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 2016

Completion Date

December 2025

Primary Completion Date

December 2025

Eligibility Criteria

        Inclusion Criteria:

          -  BMI < 35

          -  Premenopausal

          -  Uterine size <20 gw

          -  Willingness to participate to the research

          -  Uterine fibroids with typical symptoms

          -  Maximum of 4 treated fibroids

          -  Dominant fibroid >2.5cm

          -  >50% of the fibroid is treatable

        Exclusion criteria

          -  Unspecified pelvic tumours or ovarian masses, PID

          -  Major corrective surgery to uterus (simple myomectomy excluded)

          -  Major uterine anomalies

          -  Unability to calculate the volume of uterine fibroids

          -  Marked uterine calcification

          -  Marked scarring of the lower abdomen

          -  Suspicion of malignancy

          -  Marked general health problem contraindicating MRI

          -  Claustrophobia




18 Years - 50 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Kirsi M Joronen, PhD, , [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Turku University Hospital

Study Sponsor

Kirsi M Joronen, PhD, Principal Investigator, Turku University Hospital

Verification Date

April 2019